Potential role of IL-17 blocking agents in the treatment of severe COVID-19?

Br J Clin Pharmacol. 2021 Mar;87(3):1578-1581. doi: 10.1111/bcp.14437. Epub 2020 Jul 5.

Authors

Vedrana Bulat¹, Mirna Situm¹, Marija Delas Azdajic¹, Robert Likic^{2

3}

Affiliations

¹ Department of Dermatology and Venereology, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia.
² School of Medicine, University of Zagreb, Zagreb, Croatia.
³ Department of Internal Medicine, Division for Clinical Pharmacology and Therapeutics, University Hospital Centre Zagreb, Zagreb, Croatia.

No abstract available

Keywords: COVID-19; IL-17 blocking agents; SARS-CoV-2; brodalumab; ixekizumab; secukinumab.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
COVID-19 Drug Treatment*
Humans
Interleukin-17 / antagonists & inhibitors*
Th17 Cells / drug effects

Substances

Antibodies, Monoclonal, Humanized
IL17A protein, human
Interleukin-17
brodalumab
ixekizumab
secukinumab